{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:18:05Z","timestamp":1781306285696,"version":"3.54.1"},"reference-count":187,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy. Traditional chemotherapy methods not only bring serious side effects, but also lead to high recurrence rate and drug resistance in some patients. However, as an emerging therapeutic strategy, immunotherapy has shown great potential in the field of AML treatment in recent years. At present, common immunotherapy methods for AML include monoclonal antibodies, CAR-T cell therapy, and immune checkpoint inhibitors. With the deepening of research and technological progress, especially the application of nanotechnology in medicine, new immunotherapy is expected to become one of the important means for the treatment of acute myeloid leukemia in the future.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1505247","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T06:47:15Z","timestamp":1741589235000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A review of common immunotherapy and nano immunotherapy for acute myeloid leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Yaoyao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiancong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2026","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115705","article-title":"Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches","volume":"215","author":"Tosic","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.3390\/molecules27123911","article-title":"Molecular-targeted therapy of pediatric acute myeloid leukemia","volume":"27","author":"Obszanski","year":"2022","journal-title":"Molecules"},{"key":"B5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12943-021-01446-z","article-title":"Circular RNAs in acute myeloid leukemia","volume":"20","author":"Singh","year":"2021","journal-title":"Mol Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0140-6736(12)61727-9","article-title":"Acute myeloid leukaemia in adults","volume":"9","author":"Ferrara","year":"9865","journal-title":"Lancet 2013 Feb"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: from the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.3390\/molecules26113382","article-title":"A review on cancer immunotherapy and applications of nanotechnology to chemoimmunotherapy of different cancers","volume":"26","author":"Akkin","year":"2021","journal-title":"Molecules"},{"key":"B10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.817974","article-title":"Role of nanotechnology and their perspectives in the treatment of kidney diseases","volume":"12","author":"Merlin","year":"2021","journal-title":"Front Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155218","article-title":"Two effective factors in cancer: Investigating the effect of ncRNAs in cancer and also the effect of nanotherapy in its treatment","volume":"256","author":"Saleh","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.chom.2018.12.006","article-title":"Innate and adaptive immune memory: an evolutionary continuum in the host\u2019s response to pathogens","volume":"25","author":"Netea","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2012.07.007","article-title":"Control of innate and adaptive immunity by the inflammasome","volume":"14","author":"Ciraci","year":"2012","journal-title":"Microbes Infect"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2206346","article-title":"Humoral innate immunity and acute-phase proteins","volume":"388","author":"Mantovani","year":"2023","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.017","article-title":"Adaptive immunity","volume":"125","author":"Bonilla","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101819-074948","article-title":"Natural killer cells: from innate to adaptive features","volume":"39","author":"Mujal","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2174\/1389450116666150518095346","article-title":"Immunomodulatory drugs: immune checkpoint agents in acute leukemia","volume":"18","author":"Knaus","year":"2017","journal-title":"Curr Drug Targets"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration","volume":"562","author":"Deng","year":"2018","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.3390\/cells10123376","article-title":"The role of T cell immunotherapy in acute myeloid leukemia","volume":"10","author":"Hao","year":"2021","journal-title":"Cells"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.75","article-title":"Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells","volume":"26","author":"Coles","year":"2012","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3003","article-title":"Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2153-5","article-title":"Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia","volume":"105","author":"Ismail","year":"2017","journal-title":"Int J Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20010938","article-title":"Reciprocal activating interaction between natural killer cells and dendritic cells","volume":"195","author":"Gerosa","year":"2002","journal-title":"J Exp Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001802","article-title":"CD200 expression marks leukemia stem cells in human AML","volume":"4","author":"Ho","year":"2020","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1196308","DOI":"10.1080\/2162402X.2016.1196308","article-title":"Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing","volume":"5","author":"Kearney","year":"2016","journal-title":"Oncoimmunology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.3390\/cancers12082171","article-title":"Characterization of the DNAM-1, TIGIT and TACTILE axis on circulating NK, NKT-like and T cell subsets in patients with acute myeloid leukemia","volume":"12","author":"Valhondo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-365817","article-title":"Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation","volume":"118","author":"Ustun","year":"2011","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275446","article-title":"Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia","volume":"116","author":"Zhou","year":"2010","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.5.2516","article-title":"CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism","volume":"170","author":"Oida","year":"2003","journal-title":"J Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.3.1240","article-title":"Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo","volume":"170","author":"Sundstedt","year":"2003","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3010","article-title":"Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia","volume":"15","author":"Szczepanski","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9325261","article-title":"Impact of bone marrow aspirate tregs on the response rate of younger newly diagnosed acute myeloid leukemia patients","volume":"2018","author":"Delia","year":"2018","journal-title":"J Immunol Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1385\/IR:32:1-3:155","article-title":"CD25+ CD4+ regulatory T-cells in cancer","volume":"32","author":"Linehan","year":"2005","journal-title":"Immunol Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9015-y","article-title":"Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice","volume":"13","author":"Viehl","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-144485","article-title":"The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology","volume":"113","author":"Curti","year":"2009","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1865-2","article-title":"Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia","volume":"102","author":"Sun","year":"2015","journal-title":"Int J Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1469594","article-title":"VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2939","article-title":"Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment","volume":"18","author":"Lu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-730614","article-title":"MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia","volume":"129","author":"Pyzer","year":"2017","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.9.5398","article-title":"Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells","volume":"166","author":"Gabrilovich","year":"2001","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0111021","article-title":"Antigen specificity of immune suppression by myeloid-derived suppressor cells","volume":"90","author":"Solito","year":"2011","journal-title":"J Leukoc Biol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy","volume":"21","author":"Wu","year":"2022","journal-title":"Mol Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1177\/11795549211035540","article-title":"Targeting MDSC for immune-checkpoint blockade in cancer immunotherapy: current progress and new prospects","volume":"15","author":"Li","year":"2021","journal-title":"Clin Med Insights Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.2.689","article-title":"Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism","volume":"168","author":"Mazzoni","year":"2002","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24249","article-title":"Induction of myeloid-derived suppressor cells by tumor exosomes","volume":"124","author":"Xiang","year":"2009","journal-title":"Int J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108114","article-title":"Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy","volume":"235","author":"Joshi","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers6031670","article-title":"Tumor-associated macrophages as major players in the tumor microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-015-1373-0","article-title":"Tumor-associated macrophages in cancers","volume":"18","author":"Hu","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12943-019-1102-3","article-title":"Harnessing tumor-associated macrophages as aids for cancer immunotherapy","volume":"18","author":"Li","year":"2019","journal-title":"Mol Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09967-y","article-title":"Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges","volume":"13","author":"Wang","year":"2019","journal-title":"Hepatol Int"},{"key":"B61","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.54","article-title":"The role of myeloid cells in cancer therapies","volume":"16","author":"Engblom","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01614.x","article-title":"Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma","volume":"101","author":"Hasita","year":"2010","journal-title":"Cancer Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.022","article-title":"Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice","volume":"67","author":"Ma","year":"2017","journal-title":"J Hepatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.021","article-title":"Pleural effusion of patients with Malignant mesothelioma induces macrophage-mediated T cell suppression","volume":"11","author":"Lievense","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02227","article-title":"Acute myeloid leukemia cells express ICOS ligand to promote the expansion of regulatory T cells","volume":"9","author":"Han","year":"2018","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31829fb7a2","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"J Immunother"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082173","article-title":"Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1","volume":"206","author":"Kuang","year":"2009","journal-title":"J Exp Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6287","article-title":"Arginine metabolism key enzymes affect the prognosis of myelodysplastic syndrome by interfering with macrophage polarization","volume":"12","author":"Ou","year":"2023","journal-title":"Cancer Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"568:118518","DOI":"10.1016\/j.ijpharm.2019.118518","article-title":"CD123\/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape","author":"Sun","year":"2019","journal-title":"Int J Pharm"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0043","article-title":"Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML","volume":"11","author":"Mahalleh","year":"2019","journal-title":"Immunotherapy"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01626-2","article-title":"Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123","volume":"41","author":"Gauthier","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2014.896190","article-title":"Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia","volume":"7","author":"Walter","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.341","article-title":"and in vivo lysis of AML blasts by a novel CD33\/CD3-bispecific BiTE antibody construct","volume":"27","author":"Aigner","year":"2013","journal-title":"Leukemia"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0956","article-title":"Preclinical characterization of AMG 330, a CD3\/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia","volume":"13","author":"Friedrich","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B78","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1189\/jlb.0205096","article-title":"A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing","volume":"79","author":"Hernandez-Caselles","year":"2006","journal-title":"J Leukoc Biol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08033.x","article-title":"Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells","volume":"148","author":"Stein","year":"2010","journal-title":"Br J Haematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08300.x","article-title":"A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting","volume":"150","author":"Kugler","year":"2010","journal-title":"Br J Haematol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/CJI.0b013e3181dda225","article-title":"Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16","volume":"33","author":"Singer","year":"2010","journal-title":"J Immunother"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1096\/fj.11-181396","article-title":"Aminopeptidase-N\/CD13 is a potential proapoptotic target in human myeloid tumor cells","volume":"25","author":"Piedfer","year":"2011","journal-title":"FASEB J"},{"key":"B83","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-680546","article-title":"Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts","volume":"127","author":"Vasu","year":"2016","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201832","article-title":"ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile","volume":"13","author":"Kauder","year":"2018","journal-title":"PloS One"},{"key":"B86","doi-asserted-by":"publisher","first-page":"7542","DOI":"10.3390\/ijms23147542","article-title":"New frontiers in monoclonal antibodies for the targeted therapy of acute myeloid leukemia and myelodysplastic syndromes","volume":"23","author":"Gallazzi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.68","article-title":"T-cell ligands modulate the cytolytic activity of the CD33\/CD3 BiTE antibody construct, AMG 330","volume":"5","author":"Laszlo","year":"2015","journal-title":"Blood Cancer J"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmir.2019.05.008","article-title":"Targeted alpha-particle therapy for hematologic Malignancies","volume":"50","author":"Jurcic","year":"2019","journal-title":"J Med Imaging Radiat Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0184","article-title":"A new class of antibody-drug conjugates with potent DNA alkylating activity","volume":"15","author":"Miller","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B90","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205252","article-title":"CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia","volume":"104","author":"Angelova","year":"2019","journal-title":"Haematologica"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0407","article-title":"LILRB4-targeting antibody-drug conjugates for the treatment of acute myeloid leukemia","volume":"19","author":"Anami","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0742","article-title":"Characterization of SGN-CD123A, A potent CD123-directed antibody-drug conjugate for acute myeloid leukemia","volume":"17","author":"Li","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00609","article-title":"A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia","volume":"10","author":"Liao","year":"2019","journal-title":"Front Pharmacol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33690","article-title":"A phase 1b\/2 study of azacitidine with PD-L1 antibody avelumab in relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Saxena","year":"2021","journal-title":"Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: A nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discovery"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study","volume":"6","author":"Ravandi","year":"2019","journal-title":"Lancet Haematol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells","volume":"627","author":"Guan","year":"2024","journal-title":"Nature"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02041","article-title":"Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells","volume":"9","author":"Kim","year":"2018","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/14653240500499507","article-title":"CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system","volume":"8","author":"Zhong","year":"2006","journal-title":"Cytotherapy"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202","article-title":"Leukemia, lymphoma society blood cancer research P. Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B105","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.3390\/ijms22041944","article-title":"Emerging immunotherapy for acute myeloid leukemia","volume":"22","author":"Tabata","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.789","article-title":"Reprint of: building a safer and faster CAR: seatbelts, airbags, and CRISPR","volume":"24","author":"Perales","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.241","article-title":"CD33-specific chimeric antigen receptor T cells with different co-stimulators showed potent anti-leukemia efficacy and different phenotype","volume":"29","author":"Li","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/683065","article-title":"In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia","volume":"2012","author":"Dutour","year":"2012","journal-title":"Adv Hematol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am J Hematol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002779","article-title":"Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819992116","article-title":"Gene-edited stem cells enable CD33-directed immune therapy for myeloid Malignancies","volume":"116","author":"Borot","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33865","article-title":"CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"150","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-612721","article-title":"Targeting of folate receptor beta on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells","volume":"125","author":"Lynn","year":"2015","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0130","article-title":"Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor","volume":"66","author":"Zhang","year":"2006","journal-title":"Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.exphem.2013.11.008","article-title":"Differential requirement for wild-type Flt3 in leukemia initiation among mouse models of human leukemia","volume":"42","author":"Kamezaki","year":"2014","journal-title":"Exp Hematol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3016","article-title":"Novel approaches to acute myeloid leukemia immunotherapy","volume":"24","author":"Beyar-Katz","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116132","article-title":"Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective","volume":"171","author":"Wu","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B134","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.3390\/cancers14122994","article-title":"Vaccination therapy for acute myeloid leukemia: where do we stand","volume":"14","author":"Barbullushi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1007\/BF02981935","article-title":"Wilms\u2019 tumor gene WT1: its oncogenic function and clinical application","volume":"73","author":"Sugiyama","year":"2001","journal-title":"Int J Hematol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2007.119","article-title":"WT1 peptide cancer vaccine for patients with hematopoietic Malignancies and solid cancers","volume":"7","author":"Oka","year":"2007","journal-title":"ScientificWorldJournal"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0163","article-title":"CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia","volume":"100","author":"Scheibenbogen","year":"2002","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017014175","article-title":"Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia","volume":"2","author":"Maslak","year":"2018","journal-title":"Blood Adv"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03432-4","article-title":"Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide","volume":"72","author":"Naoe","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014704","article-title":"High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma","volume":"95","author":"Greiner","year":"2010","journal-title":"Haematologica"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0929-7","article-title":"Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909","volume":"60","author":"Kuball","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B142","article-title":"Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia","volume":"91","author":"Houtenbos","year":"2006","journal-title":"Haematologica"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.6.2588","article-title":"CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells","volume":"93","author":"Zhou","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B144","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1943991","article-title":"A phase I\/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients","volume":"17","author":"Chevallier","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.259457","article-title":"Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model","volume":"106","author":"Stroopinsky","year":"2021","journal-title":"Haematologica"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-780155","article-title":"Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"130","author":"Anguille","year":"2017","journal-title":"Blood"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2198-9","article-title":"A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia","volume":"67","author":"van de Loosdrecht","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30696","article-title":"Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia","volume":"123","author":"Khoury","year":"2017","journal-title":"Cancer"},{"key":"B150","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nm0598-594","article-title":"Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes","volume":"4","author":"Zitvogel","year":"1998","journal-title":"Nat Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2013.04.011","article-title":"Molecular lipidomics of exosomes released by PC-3 prostate cancer cells","volume":"1831","author":"Llorente","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-023-00810-z","article-title":"Exosomes: a potential diagnostic and treatment modality in the quest for counteracting cancer","volume":"46","author":"Patel","year":"2023","journal-title":"Cell Oncol (Dordr)"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2626-7","article-title":"Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2\/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice","volume":"140","author":"Wang","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.01.078","article-title":"Heterologous human\/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2\/HER2 mice","volume":"36","author":"Xie","year":"2018","journal-title":"Vaccine"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/srep38498","article-title":"Human adipose mesenchymal stem cell-derived exosomal-miRNAs are critical factors for inducing anti-proliferation signalling to A2780 and SKOV-3 ovarian cancer cells","volume":"6","author":"Reza","year":"2016","journal-title":"Sci Rep"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/s1658-3876(08)50011-2","article-title":"Stabilization of acute myeloid leukemia with a dendritic cell vaccine","volume":"1","author":"Massumoto","year":"2008","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.28.4.855","article-title":"Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts","volume":"28","author":"Li","year":"2006","journal-title":"Int J Oncol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.259","article-title":"Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion","volume":"32","author":"Kumar","year":"2018","journal-title":"Leukemia"},{"key":"B159","doi-asserted-by":"publisher","first-page":"14684","DOI":"10.1038\/s41598-017-14661-w","article-title":"Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia","volume":"7","author":"Hong","year":"2017","journal-title":"Sci Rep"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00496-9","article-title":"Cancer nanomedicine","volume":"22","author":"Bhatia","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.201800481","article-title":"HPMA-based nanocarriers for effective immune system stimulation","volume":"19","author":"Kramer","year":"2019","journal-title":"Macromol Biosci"},{"key":"B162","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s40820-020-00482-6","article-title":"A review on nano-based drug delivery system for cancer chemoimmunotherapy","volume":"12","author":"Mu","year":"2020","journal-title":"Nanomicro Lett"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9970-6","article-title":"Where are the nanodrugs? An industry perspective on development of drug products containing nanomaterials","volume":"18","author":"Havel","year":"2016","journal-title":"AAPS J"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9961-7","article-title":"Nanomedicines: from bench to bedside and beyond","volume":"18","author":"Havel","year":"2016","journal-title":"AAPS J"},{"key":"B165","article-title":"The nanomedicine revolution: part 1: emerging concepts","volume":"37","author":"Ventola","year":"2012","journal-title":"P T"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.08.023","article-title":"Regulatory aspects on nanomedicines","volume":"468","author":"Sainz","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"B167","article-title":"Cancer immunotherapy, part 1: current strategies and agents","volume":"42","author":"Ventola","year":"2017","journal-title":"P T"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.14.127","article-title":"Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology","volume":"9","author":"Li","year":"2014","journal-title":"Nanomedicine (Lond)"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S460047","article-title":"Biopolymer-based nanomedicine for cancer therapy: opportunities and challenges","volume":"19","author":"Wu","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"B170","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.semcancer.2019.12.004","article-title":"Glyco-nanoparticles: New drug delivery systems in cancer therapy","volume":"69","author":"Khan","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.6b15954","article-title":"Cancer-cell-specific mitochondria-targeted drug delivery by dual-ligand-functionalized nanodiamonds circumvent drug resistance","volume":"9","author":"Chan","year":"2017","journal-title":"ACS Appl Mater Interfaces"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.7b03186","article-title":"Tumor microenvironment responsive nanogel for the combinatorial antitumor effect of chemotherapy and immunotherapy","volume":"17","author":"Song","year":"2017","journal-title":"Nano Lett"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41467-019-09221-x","article-title":"Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors","volume":"10","author":"Duan","year":"2019","journal-title":"Nat Commun"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.8b00305","article-title":"Glycocalyx-mimicking nanoparticles improve anti-PD-L1 cancer immunotherapy through reversion of tumor-associated macrophages","volume":"19","author":"Zhang","year":"2018","journal-title":"Biomacromolecules"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201500089","article-title":"Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing","volume":"4","author":"Teo","year":"2015","journal-title":"Adv Healthc Mater"},{"key":"B176","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jconrel.2023.04.005","article-title":"High-throughput screens identify a lipid nanoparticle that preferentially delivers mRNA to human tumors in vivo","volume":"357","author":"Huayamares","year":"2023","journal-title":"J Control Release"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121339","article-title":"In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift","volume":"281","author":"Kheirolomoom","year":"2022","journal-title":"Biomaterials"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.7150\/thno.40291","article-title":"Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment","volume":"10","author":"Ma","year":"2020","journal-title":"Theranostics"},{"key":"B180","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.biomaterials.2018.03.013","article-title":"Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy","volume":"167","author":"Deng","year":"2018","journal-title":"Biomaterials"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.01.015","article-title":"Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts","volume":"34","author":"Lim","year":"2010","journal-title":"Leuk Res"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.07.006","article-title":"Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia","volume":"36","author":"Feldman","year":"2012","journal-title":"Leuk Res"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103984","article-title":"Real-world experience with CPX-351 in high-risk acute myeloid leukemia","volume":"185","author":"Lemoli","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S190027","article-title":"Idarubicin-loaded methoxy poly(ethylene glycol)-b-poly(l-lactide-co-glycolide) nanoparticles for enhancing cellular uptake and promoting antileukemia activity","volume":"14","author":"Liang","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"B185","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3390\/molecules24112103","article-title":"Novel targeted nano-parthenolide molecule against NF-kB in acute myeloid leukemia","volume":"24","author":"Darwish","year":"2019","journal-title":"Molecules"},{"key":"B186","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12951-021-00921-5","article-title":"Self-assembling ferritin-dendrimer nanoparticles for targeted delivery of nucleic acids to myeloid leukemia cells","volume":"19","author":"Palombarini","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2949","article-title":"Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles","volume":"76","author":"Jiang","year":"2016","journal-title":"Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1505247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T06:47:20Z","timestamp":1741589240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1505247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":187,"alternative-id":["10.3389\/fimmu.2025.1505247"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1505247","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"article-number":"1505247"}}